149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)

Abstract

19del, and 14 pts (43.8%) with exon 21 L858R. 17 pts (53.1 %) had progression on both 1 st /2 nd and 3 rd EGFR-TKIs treatment. 10 pts (31.3%) had prior anti-angiogenesis treatment. The ORR and DCR were 59.4% (95%CI 40.6-76.3) and 90.6% (95%CI 75.0-98.0), respectively. Median TTR was 80 (41-93) days. Favorable ORR was observed in all subgroups (Table ). Among 40 pts, TEAE occurred in 37 pts (92.5%), and grade 3 TEAE occurred in 13 pts (32.5%). Most common TRAE (>25%) included leukopenia, neutropenia, anemia, thrombocytopenia, alopecic, rash, and hypaesthesia. SAEs were observed in 7 pts (17.5%).Conclusions: Tislelizumab plus chemotherapy has preliminarily shown a promising anti-tumor efficacy with manageable safety profile for EGFR TKI failure pts. Efficacy and safety of the combination will be continuously monitored.Clinical trial identification: NCT04405674.